# Vebreltinib

Source: https://onco.cc/drugs/vebreltinib/  
OnCo record `vebreltinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vebreltinib is a Chinese MET inhibitor approved in 2023 for lung cancers with a MET exon 14 skipping mutation, and the first drug tested in a phase 3 trial for glioblastomas carrying a PTPRZ1-MET fusion.

## Summary

Beijing Pearl Biotechnology's vebreltinib (PLB1001, also developed as APL-101 by Apollomics) was approved by China's NMPA in November 2023 for locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping. Because it crosses the blood-brain barrier, it was also taken into a randomised phase 3 trial in secondary glioblastoma with PTPRZ1-MET fusions, a rare molecular subgroup identified by Chinese neuro-oncology groups, and a further trial in MET-altered lung cancer is registered.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: Bozitinib; APL-101; CBT-101
- Tags: pipeline; ctgov-ingest
- Code: PLB1001
- Modality: Oral selective MET tyrosine kinase inhibitor
- Mechanism: A selective, brain-penetrant inhibitor of the MET kinase; tumours with MET exon 14 skipping mutations, MET amplification or PTPRZ1-MET fusions depend on that signal.
- Approvals: CN 2023: Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping

## Sources

- ClinicalTrials.gov: trials of Vebreltinib: https://clinicaltrials.gov/search?intr=PLB1001

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [MET](https://onco.cc/targets/met/)
- trials: [A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)](https://onco.cc/trials/nct05989542/), [A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).](https://onco.cc/trials/nct06105619/), [A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive](https://onco.cc/trials/nct06930794/), [APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors](https://onco.cc/trials/nct03175224/), [Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.](https://onco.cc/trials/nct06574347/), [Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI](https://onco.cc/trials/nct06343064/)

---
JSON: https://onco.cc/api/v1/entities/vebreltinib.json